Winfried B Graninger

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4066173/publications.pdf

Version: 2024-02-01

103 papers 8,094 citations

76196 40 h-index 49773 87 g-index

105 all docs 105
docs citations

105 times ranked 8329 citing authors

#	Article	IF	CITATIONS
1	Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force. Annals of the Rheumatic Diseases, 2016, 75, 3-15.	0.5	1,114
2	2019 European League Against Rheumatism/American College of Rheumatology Classification Criteria for Systemic Lupus Erythematosus. Arthritis and Rheumatology, 2019, 71, 1400-1412.	2.9	1,098
3	2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. Annals of the Rheumatic Diseases, 2019, 78, 1151-1159.	0.5	759
4	Treat-to-target in systemic lupus erythematosus: recommendations from an international task force. Annals of the Rheumatic Diseases, 2014, 73, 958-967.	0.5	558
5	Safety and efficacy of tumor necrosis factor ? blockade in systemic lupus erythematosus: An open-label study. Arthritis and Rheumatism, 2004, 50, 3161-3169.	6.7	317
6	A framework for remission in SLE: consensus findings from a large international task force on definitions of remission in SLE (DORIS). Annals of the Rheumatic Diseases, 2017, 76, 554-561.	0.5	268
7	Therapeutic Potential of Targeting the Th $17/T$ reg Axis in Autoimmune Disorders. Molecules, 2017, 22, 134.	1.7	180
8	Adverse events and efficacy of TNF-Â blockade with infliximab in patients with systemic lupus erythematosus: long-term follow-up of 13 patients. Rheumatology, 2009, 48, 1451-1454.	0.9	173
9	Borderline Pulmonary Arterial Pressure Is Associated with Decreased Exercise Capacity in Scleroderma. American Journal of Respiratory and Critical Care Medicine, 2009, 180, 881-886.	2.5	141
10	Autoimmune response to the spliceosome. Arthritis and Rheumatism, 1995, 38, 777-785.	6.7	138
11	Extracorporeal photochemotherapy for the treatment of systemic lupus erythematosus. A Pilot study. Arthritis and Rheumatism, 1992, 35, 319-324.	6.7	129
12	A randomized, double-blind, placebo-controlled trial of photopheresis in systemic sclerosis. Journal of the American Academy of Dermatology, 2006, 54, 793-799.	0.6	117
13	Demonstration of a new antinuclear antibody (ANTI-RA33) that is highly specific for rheumatoid arthritis. Arthritis and Rheumatism, 1989, 32, 1515-1520.	6.7	113
14	Effects of short-term infliximab therapy on autoantibodies in systemic lupus erythematosus. Arthritis and Rheumatism, 2007, 56, 274-279.	6.7	102
15	Consensus statement on blocking the effects of interleukin-6 and in particular by interleukin-6 receptor inhibition in rheumatoid arthritis and other inflammatory conditions. Annals of the Rheumatic Diseases, 2013, 72, 482-492.	0.5	102
16	High levels ofbcl-2 protein in circulating t lymphocytes, but not b lymphocytes, of patients with systemic lupus erythematosus. Arthritis and Rheumatism, 1994, 37, 1423-1430.	6.7	101
17	The effect of vitamin D supplementation on peripheral regulatory T cells and \hat{l}^2 cell function in healthy humans: a randomized controlled trial. Diabetes/Metabolism Research and Reviews, 2011, 27, 942-945.	1.7	97
18	Disparity between ultrasound and clinical findings in psoriatic arthritis. Annals of the Rheumatic Diseases, 2014, 73, 1529-1536.	0.5	95

#	Article	IF	CITATIONS
19	Tocilizumab in patients with active rheumatoid arthritis and inadequate responses to DMARDs and/or TNF inhibitors: a large, open-label study close to clinical practice. Annals of the Rheumatic Diseases, 2012, 71, 1950-1954.	0.5	91
20	Vitamin D supplementation and regulatory T cells in apparently healthy subjects: vitamin D treatment for autoimmune diseases?. Israel Medical Association Journal, 2010, 12, 136-9.	0.1	90
21	Cholecalciferol supplementation improves suppressive capacity of regulatory T-cells in young patients with new-onset type 1 diabetes mellitus $\hat{a} \in \mathbb{C}$ A randomized clinical trial. Clinical Immunology, 2015, 161, 217-224.	1.4	85
22	Parenteral administration of 8-methoxypsoralen in photopheresis. Journal of the American Academy of Dermatology, 1993, 28, 580-584.	0.6	81
23	Activation of Fas inhibits heatâ€induced activation of HSF1 and upâ€regulation of hsp70. FASEB Journal, 1999, 13, 833-842.	0.2	72
24	Severe infections in plasmapheresis-treated systemic lupus erythematosus. Arthritis and Rheumatism, 1998, 41, 414-420.	6.7	71
25	Treating Rheumatoid Arthritis to Target: multinational recommendations assessment questionnaire. Annals of the Rheumatic Diseases, 2011, 70, 1999-2002.	0.5	71
26	Early endoscopy in systemic sclerosis without gastrointestinal symptoms. Rheumatology International, 2012, 32, 165-168.	1.5	70
27	Effects of Cartilage-Derived Morphogenetic Proteins and Osteogenic Protein-1 on Osteochondrogenic Differentiation of Periosteum-Derived Cells*. Endocrinology, 2001, 142, 2087-2094.	1.4	68
28	Listeria -Associated Arthritis in a Patient Undergoing Etanercept Therapy: Case Report and Review of the Literature. Journal of Clinical Microbiology, 2005, 43, 2537-2541.	1.8	67
29	Pulmonary arterial hypertension therapy may be safe and effective in patients with systemic sclerosis and borderline pulmonary artery pressure. Arthritis and Rheumatism, 2012, 64, 1257-1262.	6.7	65
30	Epigenetic differences in human cartilage between mild and severe OA. Journal of Orthopaedic Research, 2014, 32, 1636-1645.	1.2	64
31	Persistent functional and social benefit 5 years after a multidisciplinary arthritis training program. Archives of Physical Medicine and Rehabilitation, 1999, 80, 1282-1287.	0.5	63
32	Early spondyloarthritis: usefulness of clinical screening. Rheumatology, 2009, 48, 812-816.	0.9	63
33	Ultrasound for diagnosis of carpal tunnel syndrome: comparison of different methods to determine median nerve volume and value of power Doppler sonography. Annals of the Rheumatic Diseases, 2013, 72, 1934-1939.	0.5	63
34	High-dose cholecalciferol supplementation significantly increases peripheral CD4+ Tregs in healthy adults without negatively affecting the frequency of other immune cells. European Journal of Nutrition, 2014, 53, 751-759.	1.8	63
35	STIMULATORY EFFECTS OF CARTILAGE-DERIVED MORPHOGENETIC PROTEINS 1 AND 2 ON OSTEOGENIC DIFFERENTIATION OF BONE MARROW STROMAL CELLS. Cytokine, 2000, 12, 1630-1638.	1.4	54
36	Purification of human basophils and mast cells by multistep separation technique and mAb to CDw17 and. Journal of Immunological Methods, 1995, 182, 115-129.	0.6	51

#	Article	IF	CITATIONS
37	Rituximab in psoriatic arthritis: an exploratory evaluation. Annals of the Rheumatic Diseases, 2012, 71, 1868-1871.	0.5	51
38	Ultrasound composite scores for the assessment of inflammatory and structural pathologies in Psoriatic Arthritis (PsASon-Score). Arthritis Research and Therapy, 2014, 16, 476.	1.6	51
39	Soluble Intercellular Adhesion Molecule-1 (sICAM-1) in Patients with Rheumatoid Arthritis and Systemic Lupus Erythematosus. Clinical Immunology and Immunopathology, 1993, 68, 74-78.	2.1	48
40	Immunization of patients with rheumatoid arthritis with antitumor necrosis factor \hat{l} therapy and methotrexate. Current Opinion in Rheumatology, 2008, 20, 295-299.	2.0	44
41	It's more than dryness and fatigue: The patient perspective on health-related quality of life in Primary Sjögren's Syndrome - A qualitative study. PLoS ONE, 2017, 12, e0172056.	1.1	43
42	Novel Senescent Regulatory T-Cell Subset with Impaired Suppressive Function in Rheumatoid Arthritis. Frontiers in Immunology, 2017, 8, 300.	2.2	42
43	Cardiac involvement in systemic sclerosis. Arthritis and Rheumatism, 1992, 35, 1356-1361.	6.7	40
44	Senescent T-Cells Promote Bone Loss in Rheumatoid Arthritis. Frontiers in Immunology, 2018, 9, 95.	2.2	40
45	Patient education, disease activity and physical function: can we be more targeted? A cross sectional study among people with rheumatoid arthritis, psoriatic arthritis and hand osteoarthritis. Arthritis Research and Therapy, 2013, 15, R156.	1.6	39
46	Relapse of Diabetes After Interruption of Chronic Administration of Anti-Tumor Necrosis Factor-Â Antibody Infliximab: A case observation. Diabetes Care, 2006, 29, 1712-1713.	4.3	37
47	B lymphocyte-typing for prediction of clinical response to rituximab. Arthritis Research and Therapy, 2012, 14, R161.	1.6	37
48	European League Against Rheumatism (EULAR)/American College of Rheumatology (ACR) SLE classification criteria item performance. Annals of the Rheumatic Diseases, 2021, 80, 775-781.	0.5	37
49	Ultrasound-Defined Remission and Active Disease in Rheumatoid Arthritis: Association with Clinical and Serologic Parameters. Seminars in Arthritis and Rheumatism, 2012, 41, 761-767.	1.6	36
50	Real-Time Sonoelastography of Salivary Glands for Diagnosis and Functional Assessment of Primary Sjögren's Syndrome. Ultrasound in Medicine and Biology, 2014, 40, 2759-2767.	0.7	36
51	Comparison of tocilizumab as monotherapy or with add-on disease-modifying antirheumatic drugs in patients with rheumatoid arthritis and inadequate responses to previous treatments: an open-label study close to clinical practice. Clinical Rheumatology, 2015, 34, 563-571.	1.0	36
52	Performance of the 2019 EULAR/ACR classification criteria for systemic lupus erythematosus in early disease, across sexes and ethnicities. Annals of the Rheumatic Diseases, 2020, 79, 1333-1339.	0.5	35
53	IL-1 receptor blockade skews inflammation towards Th2 in a mouse model of systemic sclerosis. European Respiratory Journal, 2019, 54, 1900154.	3.1	31
54	Immunoadsorption as a rescue therapy in systemic lupus erythematosus: considerations on safety and efficacy. Wiener Klinische Wochenschrift, 2004, 116, 716-724.	1.0	28

#	Article	IF	CITATIONS
55	Changes in pulmonary exercise haemodynamics in scleroderma: a 4-year prospective study. European Respiratory Journal, 2017, 50, 1601708.	3.1	28
56	Photopheresis for the Treatment of Lupus Erythematosus Annals of the New York Academy of Sciences, 1991, 636, 340-356.	1.8	27
57	Treatment of Rheumatoid Arthritis by TNF-Blocking Agents. International Archives of Allergy and Immunology, 2002, 127, 10-14.	0.9	24
58	A combination of cellular biomarkers predicts failure to respond to rituximab in rheumatoid arthritis: a 24-week observational study. Arthritis Research and Therapy, 2016, 18, 190.	1.6	24
59	BMP-6-induced osteogenic differentiation of mesenchymal cell lines is not modulated by sex steroids and resveratrol. Cytokine, 2003, 23, 133-137.	1.4	23
60	Influence of resveratrol on rheumatoid fibroblast-like synoviocytes analysed with gene chip transcription. Phytomedicine, 2013, 20, 310-318.	2.3	22
61	Effects of Cartilage-Derived Morphogenetic Proteins and Osteogenic Protein-1 on Osteochondrogenic Differentiation of Periosteum-Derived Cells. , 0, .		22
62	Treatment of systemic lupus erythematosus by immunoadsorption in a patient suffering from tuberculosis. American Journal of Kidney Diseases, 2002, 39, 415-418.	2.1	21
63	Sonographic assessment of interstitial lung disease in patients with rheumatoid arthritis, systemic sclerosis and systemic lupus erythematosus. Clinical and Experimental Rheumatology, 2015, 33, S87-91.	0.4	21
64	The MHC2TA -168A>G gene polymorphism is not associated with rheumatoid arthritis in Austrian patients. Arthritis Research and Therapy, 2006, 8, R97.	1.6	20
65	Exercise Pulmonary Resistances Predict Long-Term Survival in Systemic Sclerosis. Chest, 2021, 159, 781-790.	0.4	20
66	Sphingosine 1â€Phosphate Counteracts the Effects of Interleukinâ€1β in Human Chondrocytes. Arthritis and Rheumatism, 2013, 65, 2113-2122.	6.7	18
67	Induction of sustained remission in early inflammatory arthritis with the combination of infliximab plus methotrexate: the DINORA trial. Arthritis Research and Therapy, 2018, 20, 174.	1.6	18
68	Lymphopenia in primary Sjögren's syndrome is associated with premature aging of naÃ⁻ve CD4+ T cells. Rheumatology, 2021, 60, 588-597.	0.9	18
69	The use and diagnostic value of testing myositis-specific and myositis-associated autoantibodies by line immuno-assay: a retrospective study. Therapeutic Advances in Musculoskeletal Disease, 2020, 12, 1759720X2097590.	1.2	16
70	Whole body hyperthermia treatment increases interleukin 10 and toll-like receptor 4 expression in patients with ankylosing spondylitis: A pilot study. International Journal of Hyperthermia, 2014, 30, 393-401.	1.1	15
71	The association of clinical parameters and ultrasound verified inflammation with patients' and physicians' global assessments in psoriatic arthritis. Seminars in Arthritis and Rheumatism, 2016, 46, 183-189.	1.6	14
72	S?zary syndrome and seronegative polyarthritis: Treatment with extracorporeal photochemotherapy. Journal of the American Academy of Dermatology, 2003, 48, 220-226.	0.6	13

#	Article	IF	CITATIONS
73	Assessing health-related quality of life in primary Sjögren's syndrome—The PSS-QoL. Seminars in Arthritis and Rheumatism, 2018, 48, 105-110.	1.6	13
74	Evaluating current definitions of low disease activity in psoriatic arthritis using ultrasound. Rheumatology, 2019, 58, 2212-2220.	0.9	12
75	Drug interactions in the treatment of rheumatoid arthritis and psoriatic arthritis. Rheumatology International, 2020, 40, 511-521.	1.5	12
76	Weakly positive tests and chronologic variation of the QuantiFERON assay: A retrospective appraisal of usefulness. Tuberculosis, 2013, 93, 647-653.	0.8	10
77	The Value of Median Nerve Sonography as a Predictor for Short- and Long-Term Clinical Outcomes in Patients with Carpal Tunnel Syndrome: A Prospective Long-Term Follow-Up Study. PLoS ONE, 2016, 11, e0162288.	1.1	10
78	Effect of Lamininâ€A4 inhibition on cluster formation of human osteoarthritic chondrocytes. Journal of Orthopaedic Research, 2016, 34, 419-426.	1.2	9
79	Transient hypopituitarism in a patient with nephropathia epidemica. BMJ Case Reports, 2009, 2009, bcr0220091538-bcr0220091538.	0.2	9
80	New onset psoriasis in a patient receiving abatacept for rheumatoid arthritis. BMJ Case Reports, 2009, 2009, bcr0920080845-bcr0920080845.	0.2	9
81	Oral gold therapy in a patient with rheumatoid arthritis and preexisting uremia. Arthritis and Rheumatism, 1985, 28, 710-712.	6.7	7
82	One-year inhibition of tumor necrosis factor-l±: a major success or a larger puzzle?. Current Opinion in Rheumatology, 2001, 13, 209-213.	2.0	7
83	Impairment of chondrocyte biosynthetic activity by exposure to 3-tesla high-field magnetic resonance imaging is temporary. Arthritis Research and Therapy, 2006, 8, R106.	1.6	7
84	The Immunosuppressant FTY720 (Fingolimod) enhances Glycosaminoglycan depletion in articular cartilage. BMC Musculoskeletal Disorders, 2011, 12, 279.	0.8	7
85	Median time to low disease activity is shorter in tocilizumab combination therapy with csDMARDs as compared to tocilizumab monotherapy in patients with active rheumatoid arthritis and inadequate responses to csDMARDs and/or TNF inhibitors: sub-analysis of the Swiss and Austrian patients from the ACT-SURE study. Clinical Rheumatology, 2017, 36, 2187-2192.	1.0	6
86	Ultrasound verified enthesophytes are associated with radiographic progression at entheses in psoriatic arthritis. Rheumatology, 2020, 59, 2893-2897.	0.9	6
87	Ultrasound in osteoarthritis of the hand: a comparison to computed tomography and histology. Rheumatology, 2022, 61, SI73-SI80.	0.9	5
88	Chondrocyte cultures from human proximal interphalangeal finger joints. Journal of Orthopaedic Research, 2016, 34, 1569-1575.	1.2	4
89	The effect of disease modifying therapies on CD62L expression in multiple sclerosis. Multiple Sclerosis Journal - Experimental, Translational and Clinical, 2018, 4, 205521731880081.	0.5	4
90	Go Ask Your Patients! PSS-QoL Reported Perception of Dryness Correlates With Lacrimal and Salivary Flow in Primary Sjögren's Syndrome. Frontiers in Medicine, 2021, 8, 660580.	1.2	4

#	Article	IF	CITATIONS
91	Rituximab as a Treatment Option after Autologous Hematopoietic Stem Cell Transplantation in a Patient with Systemic Sclerosis. Journal of Personalized Medicine, 2021, 11, 600.	1.1	4
92	Treatment of rheumatoid arthritis in the 21st century: targeting B-lymphocytes. Wiener Medizinische Wochenschrift, 2006, 156, 61-67.	0.5	3
93	High disease activity of ankylosing spondylitis in the community before the introduction of tumour necrosis factor blockers. Annals of the Rheumatic Diseases, 2006, 66, 561-562.	0.5	3
94	High Prevalence of Ultrasound Verified Enthesitis in Patients With Inflammatory Bowel Disease With or Without Spondylarthritis. Frontiers in Medicine, 2021, 8, 637459.	1.2	3
95	Unusual deterioration in a patient with multiple sclerosis on natalizumab therapy. Neurology: Neuroimmunology and NeuroInflammation, 2014, 1, e1.	3.1	2
96	Severe infections in plasmapheresis-treated systemic lupus erythematosus., 1998, 41, 414.		2
97	The role of tender and swollen joints for the assessment of inflammation in PsA using ultrasound. Rheumatology, 2022, 61, SI92-SI96.	0.9	2
98	The value of MRI compared to conventional radiography in analysing morphologic changes in the spine in axial spondyloarthritis. Insights Into Imaging, 2021, 12, 183.	1.6	2
99	Response to: †Paying attention to carpal tunnel contents lesions: ultrasound for evaluation of carpal tunnel syndrome' by zhu and Liu. Annals of the Rheumatic Diseases, 2014, 73, e17-e17.	0.5	1
100	Clinical-Pathological Conference Series from the Medical University of Graz. Wiener Klinische Wochenschrift, 2017, 129, 145-152.	1.0	1
101	Clinical-Pathological Conference Series from the Medical University of Graz. Wiener Klinische Wochenschrift, 2016, 128, 846-853.	1.0	0
102	SAT0272â€RITUXIMAB SIGNIFICANTLY DIMINISHES CD86+ B CELLS IN SYSTEMIC SCLEROSIS. , 2019, , .		0
103	O8â€Performance of the EULAR/ACR 2019 classification criteria for systemic lupus erythematosus in men, ethnicities, and early disease. , 2020, , .		O